After conducting an examination of the chemicals found in smokeless cigarettes, the United States Food and Drug Administration (FDA) announced serious concerns. Scientists stated that of the 19 brands examined, most had manufacturing quality issues that point out there are no effective quality control standards in place. In addition, low levels of nicotine were found in all but one of the nicotine-free varieties, and several versions with the same nicotine content labeling distributed drastically variable amounts of nicotine when activated by inhaling. The researchers also noted tobacco specific nitrosamines, cancer-causing agents, in nearly half of the samples tested.
The Electronic Cigarette Association did not dispute the results of the FDA study, but stated that they are being looked at out of context. First, the Association maintained that the testing was too "narrow to reach any valid and reliable conclusions." Second, the results were published without comparison to nicotine replacement therapies that are FDA approved, which contain similar levels of the same toxins.
The Smokeless Cigarette Association did not dispute the results of the FDA study, but stated that they are being looked at out of context. First, the Association maintained that the testing was too "narrow to reach any valid and dependable conclusions." Second, the results were published without comparison to nicotine replacement therapies that are FDA approved, which contain similar levels of the same toxins.
The industry responded by taking their case to federal court. Electronic cigarette manufacturers argued that the product is marketed and labeled for "smoking pleasure," rather than as a therapeutic or smoking cessation product, and as such, should fall under the Family Smoking Prevention and Tobacco Control Act of 2009 (Tobacco Act). The U.S. Court of Appeals supported the electronic cigarette makers' position, and decided that the FDA cannot regulate e-cigarettes as a drug delivery device the same way nicotine replacement therapies are regulated. No appeal was filed, and the FDA announced plans to develop appropriate regulations for electronic cigarettes under the Tobacco Act.
The industry responded by taking their case to federal court. Electronic cigarette manufacturers argued that the product is marketed and labeled for "smoking pleasure," rather than as a therapeutic or smoking cessation product, and as such, should fall under the Family Smoking Prevention and Tobacco Control Act of 2009 (Tobacco Act). The U.S. Court of Appeals supported the electronic cigarette makers' position, and decided that the FDA cannot regulate e-cigarettes as a drug delivery device the same way nicotine replacement therapies are regulated. No appeal was filed, and the FDA announced plans to develop appropriate regulations for electronic cigarettes under the Tobacco Act.
The Electronic Cigarette Association did not dispute the results of the FDA study, but stated that they are being looked at out of context. First, the Association maintained that the testing was too "narrow to reach any valid and reliable conclusions." Second, the results were published without comparison to nicotine replacement therapies that are FDA approved, which contain similar levels of the same toxins.
The Smokeless Cigarette Association did not dispute the results of the FDA study, but stated that they are being looked at out of context. First, the Association maintained that the testing was too "narrow to reach any valid and dependable conclusions." Second, the results were published without comparison to nicotine replacement therapies that are FDA approved, which contain similar levels of the same toxins.
The industry responded by taking their case to federal court. Electronic cigarette manufacturers argued that the product is marketed and labeled for "smoking pleasure," rather than as a therapeutic or smoking cessation product, and as such, should fall under the Family Smoking Prevention and Tobacco Control Act of 2009 (Tobacco Act). The U.S. Court of Appeals supported the electronic cigarette makers' position, and decided that the FDA cannot regulate e-cigarettes as a drug delivery device the same way nicotine replacement therapies are regulated. No appeal was filed, and the FDA announced plans to develop appropriate regulations for electronic cigarettes under the Tobacco Act.
The industry responded by taking their case to federal court. Electronic cigarette manufacturers argued that the product is marketed and labeled for "smoking pleasure," rather than as a therapeutic or smoking cessation product, and as such, should fall under the Family Smoking Prevention and Tobacco Control Act of 2009 (Tobacco Act). The U.S. Court of Appeals supported the electronic cigarette makers' position, and decided that the FDA cannot regulate e-cigarettes as a drug delivery device the same way nicotine replacement therapies are regulated. No appeal was filed, and the FDA announced plans to develop appropriate regulations for electronic cigarettes under the Tobacco Act.
About the Author:
Vapor cigarettes are a great way to quit smoking.You can watch videos and read about different brands of smokeless cigarette here.